Cytochrome P450 2J2 oxidizes arachidonic acid to a series of epoxyeicosatrienoic acid (EET) isomers in human tissues. EETs regulate numerous homeostatic processes, including cytoprotective and proliferative responses against injurious stresses.
pendent activation of CYP2J2 expression, as well as the bZIP factors Nrf2 and c-Jun; chromatin immunoprecipitation assays revealed a pronounced increase in binding of these bZIP factors to the CYP2J2 5Ј-flank. Transient transfection analysis using deletion constructs and gel-shift assays were consistent with a role for the Ϫ105/Ϫ88 region of CYP2J2 in c-Jun/Nrf2 responsiveness. Using a series of mutant expression plasmids, we identified c-Jun as the critical partner in CYP2J2 transactivation. Coimmunoprecipitation experiments confirmed the importance of the leucine zipper region of Nrf2 in the enhancement of c-Jun-dependent transactivation of CYP2J2. Agents that activate CYP2J2 expression may offer a new approach to using the beneficial effects of EETs in cells.
The arachidonic acid epoxygenase cytochrome P450 (P450) 2J2 is widely expressed in many human tissues, including liver, heart, lung, and intestine, and catalyzes the formation of all four regioisomeric epoxyeicosatrienoic acids (EETs) Scarborough et al., 1999) that modulate a range of cellular processes. EETs not only regulate ion channel activity in cardiomyocytes (Lee et al., 1999) and inhibit inflammation (Node et al., 1999) but also inhibit apoptosis (Chen et al., 2001) , enhance the recovery of endothelial cells from hypoxia-reoxygenation injury (Yang et al., 2001) , and stimulate cell growth and migration (Chen et al., 1998; Potente et al., 2002; Sun et al., 2002) . Thus, factors that have the potential to alter EET production may also modulate cell viability and influence the development of disease after injury (Chen et al., 2001; Yang et al., 2001; Kroetz and Zeldin, 2002) . Unlike other P450 epoxygenases, CYP2J2 mediates the formation of 8,9-EET, which has been extracted from human liver and heart and is an important regulator of cell proliferation (Pozzi et al., 2005) . Thus, CYP2J2 seems to be functionally important in the range of tissues in which it is expressed.
A more detailed understanding of the regulation of the CYP2J2 EET synthase may lead to the development of new pharmacological strategies to alter the pathogenesis of disease (Yang et al., 2001; Kroetz and Zeldin, 2002) . The interplay between members of the activator protein-1 (AP-1) complex of leucine zipper (bZIP) transcription factors has been found to regulate basal CYP2J2 expression in human liverderived cells (Marden et al., 2003; Marden and Murray, 2005) . Thus, c-Jun homodimers supported CYP2J2 expression in HepG2 cells cultured in a normoxic environment and activated CYP2J2-luciferase reporter constructs via AP-1-like gene elements in the CYP2J2 upstream region. Under hypoxic conditions (ϳ1% O 2 ), another bZIP factor, c-Fos, was activated, resulting in impaired regulation of CYP2J2; in accord with this finding, c-Jun/c-Fos heterodimers abrogated the activity of CYP2J2-driven luciferase reporters (Marden et al., 2003) . Thus, the intracellular composition of bZIP transcription factors has emerged as an important determinant of constitutive CYP2J2 expression in cells.
Strategies to activate CYP2J2 expression could enable the therapeutic exploitation of some of the beneficial actions of EETs in cells. Although the induction of many P450 genes by drugs and other xenobiotics is mediated by activated nuclear and aryl hydrocarbon receptors (Waxman, 1999) , characteristic response elements for these transcription factors have not been detected in the CYP2J2 upstream sequence (Marden et al., 2003) . Consistent with this observation, CYP2J2 seems unresponsive to typical xenobiotic inducers Scarborough et al., 1999) . Instead, because c-Jun is important in the maintenance of constitutive CYP2J2 expression and forms dimers with the antioxidant-inducible bZIP factor NF-E2-related factor-2 (Nrf2) (Yu et al., 2000; Yuan et al., 2006) , we tested whether this system may regulate CYP2J2 expression. The principal finding to emerge from the present study was that treatment of HepG2 cells with butylated hydroxyanisole (BHA), an antioxidant chemical that activates Nrf2 (Yu et al., 1997; Dinkova-Kostova et al., 2002) , increased CYP2J2 expression in HepG2 cells. In accord with these findings, CYP2J2-luciferase reporter constructs were also responsive to BHA, which was dependent on the binding of c-Jun and Nrf2 to an atypical AP-1-like element in the CYP2J2 upstream region near Ϫ105/Ϫ88 relative to the translational start site. Using mutagenized expression constructs, a critical role for the transactivation domain of c-Jun in CYP2J2 activation was found, whereas enhanced transactivation by the Nrf2/c-Jun combination was dependent on dimerization between leucine residues in the bZIP region, but not on the DNA-binding or transactivation domains of Nrf2.
Materials and Methods
Chemicals and Reagents. The wild-type c-Jun and Nrf2 expression plasmids were generously provided by Dr. Kazuhiko Imakawa (Faculty of Agriculture, University of Tokyo, Tokyo, Japan) and Dr. Volker Blank (Faculty of Medicine, McGill University, Montreal, QC, Canada), respectively. TRI RNA extraction reagent was from Molecular Research Centre (Astral Scientific, Caringbah, NSW, Australia), restriction enzymes were from New England Biolabs (Arundel, QLD, Australia) unless otherwise specified, and Effectene transfection reagent was from QIAGEN (Doncaster, VIC, Australia). Oligonucleotides were synthesized by Geneworks (Adelaide, SA, Australia).
Antibodies directed against c-Jun, Nrf2, and ubiquitin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), whereas anti-phosphoserine 63 -c-Jun and anti-phosphoserine 40 -Nrf2 were from Cell Signaling Technology (Danvers, MA) and Epitomics Inc. (Burlingame, CA), respectively. Rabbit anti-(rat CYP2J4) IgG, which is crossreactive with human CYP2J2, was generously provided by Dr. Qing-Yu Zhang (New York State Department of Health, Albany, NY) (Xie et al., 2000) . ␣-Tubulin antibody, protease inhibitors, 2(3)-tert-butyl-4-hydroxyanisole (BHA), and other chemicals were from Sigma-Aldrich (Castle Hill, NSW, Australia). Gas chromatography-mass spectrometry indicated that the purity of the BHA preparation was at least 99%; potential contaminants such as tert-butylhydroquinone were not detected. SDS and other reagents for electrophoresis were from Bio-Rad (Richmond, CA). High-performance liquid chromatography-grade solvents were from Rhone-Poulenc (Baulkham Hills, NSW, Australia), and analytical reagents were from Ajax (Sydney, NSW, Australia). Hyperfilm-MP, Hybond-N ϩ filters, and reagents for enhanced chemiluminescence were from GE Healthcare (Rydalmere, NSW, Australia).
Cell Culture and Western Blotting. HepG2 cells (American Type Culture Collection, Manassas, VA) at passage 6 were used in all experiments. Cells were treated with BHA (10-100 M) in 0.1% dimethyl sulfoxide (DMSO) in serum-free Dulbecco's modified Eagle's medium and replenished at 6, 12, 18, and 24 h, and again at 48 h, after which cells were harvested at 72 h. Cell lysates (100 g of protein/lane) were electrophoresed on 10% SDS-polyacrylamide gels, transferred to nitrocellulose, and then subjected to Western immunoblotting with polyclonal anti-(rat CYP2J4) (16 g/ml), anti-Nrf2 (2 g/ ml), anti-c-Jun (2 g/ml), anti-␣-tubulin (2 g/ml), anti-phosphoserine 63 -c-Jun (1:1000 dilution), or anti-phosphoserine 40 -Nrf2 (1:1000 dilution) as described previously (Marden et al., 2003) . Preliminary experiments established the linearity of the signal response on immunoblots under these conditions. RNA Extraction and Real-Time PCR. Cellular RNA was extracted with TRI reagent and was subjected to real-time PCR analysis (SYBR Green PCR master mix; QIAGEN) in a Rotor Gene 6000 instrument (Corbett Life Science, Mortlake, NSW, Australia). Thermal cycling was carried out as follows: 50°C for 30 min, 95°C for 15 min as initial denaturing, followed by 40 cycles of 94°C for 15 s, 55 to 57.5°C for 30 s (CYP2J2, c-Jun, and ␤-actin at 55°C, and Nrf2 at 57.5°C; primer sequences are shown in Table 1 ), and 72°C for 30 s. Threshold cycles (CT values) were determined and normalized using appropriate cDNA plasmid inputs (pTOPO vector; Invitrogen) without reverse transcriptase polymerase mix. Product DNA was quantified from standards run under the same conditions.
Cloning of Mutagenized Expression Plasmids. A dominantnegative c-Jun expression plasmid (DN-c-Jun) analogous to TAM67 (Brown et al., 1993) was constructed by introducing BglII sites in the native sequence (mutagenesis primers in Table 1 ), followed by digestion and religation. Thus, the sequence corresponding to the first 120 amino acids was deleted, and the nt encoding Ala121 to Glu122 were mutagenized to encode methionine-threonine, which are the first two residues in the native sequence of c-Jun. Nrf2 mutant constructs were also prepared by site-directed mutagenesis. In Nrf2mtbZIP, the leucine residues in the fifth and sixth heptads of the bZIP domain (Leu537 and Leu544) were replaced by alanine residues, whereas in the DNA binding domain mutant Nrf2⌬DBD, the basic region between Arg499 and Lys518 encoded by nt 1495 to 1548, was deleted (mutagenesis primers in Table 1 ). The DN-Nrf2 construct was described previously by Yu et al. (2000) , in which nt 4-1268 were deleted and that resulted in deletion of Asp2-Thr408, was prepared using the mutagenesis primers in Table 1 . The pcDNA3.1-c-Jun-FLAG (c-Jun-FLAG) construct was prepared by directional PCR cloning using restriction sites HindIII and XbaI. All constructs were confirmed by bidirectional sequencing (ABI Prism Big Dye; Applied Biosystems, Foster City, CA).
Transient Transfection Analysis of the Activation of the Human CYP2J2 Promoter. The CYP2J2-luciferase reporter constructs p2J2(Ϫ2341/ϩ98), p2J2(Ϫ1228/ϩ98), p2J2(Ϫ152/ϩ98), p2J2(Ϫ122/ϩ98), and p2J2(Ϫ82/ϩ98) were described previously (Marden et al., 2003; Marden and Murray, 2005) . The construct p2J2(Ϫ152/ ϩ98; mtϪ105/Ϫ88), containing the mutagenized region Ϫ105/Ϫ88 was generated from p2J2(Ϫ152/ϩ98) using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Willoughby, NSW, Australia); oligonucleotide sequences are shown in Table 1 .
HepG2 cells (5 ϫ 10 4 cells/well in 96-well plates) were cotransfected (Effectene reagent) with CYP2J2 promoter constructs (300 ng/well) and a phRG-TK-Renilla reniformis expression plasmid (60 ng/well to standardize transfection efficiency). Wild-type and mutagenized Nrf2 and c-Jun expression plasmids were added at 150 ng/well, with salmon sperm DNA used to ensure equivalent loading in transfections. Seventy-two hours later, luciferase and R. reniformis activities were measured by Vector 3 luminometry (Dual-Glo; Promega, Alexandria, NSW, Australia). Transfections were performed in quadruplicate and in three independent experiments. Electromobility Shift Assay. Nuclear protein (NP) extracts were prepared from untransfected HepG2 cells or cells that had been transfected for 24 h with Nrf2 and c-Jun expression plasmids (500 ng of each/6 ϫ 10 5 cells) and used in electromobility shift assay (EMSA)
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Lee and Murray at ASPET Journals on April 28, 2017 molpharm.aspetjournals.org analysis as described previously (Marden et al., 2003) . Oligonucleotides used as 32 P-labeled probes or competitors in EMSAs are shown in Table 1 . In supershift experiments, NP extracts were incubated overnight at 4°C with anti-c-Jun and anti-Nrf2 antibodies alone or in combination (5 g each) before the binding reaction; the nonspecific anti-ubiquitin antibody was the negative control.
Chromatin Immunoprecipitation Assay. In vivo binding of the bZIP transcription factors c-Jun and Nrf2 to the human CYP2J2 promoter region was investigated by chromatin immunoprecipitation (ChIP) assay essentially as described previously (Fiala-Beer et al., 2007) with minor modifications. In brief, HepG2 cell monolayers were treated with 1% formaldehyde in Dulbecco's modified Eagle's medium for 10 min at 37°C. After treatment with 125 mM glycine to terminate the cross-linking reaction, cells were washed twice in ice-cold phosphate-buffered saline containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 5 g/ml leupeptin, and 1 g/ml pepstatin A), and then lysed and sonicated as described previously (Fiala-Beer et al., 2007) . Chromatin samples were incubated overnight at 4°C with antibodies directed against the N terminus of c-Jun or the C terminus of Nrf2 (5 g), and PCR (primer sequences in Table 1 ) was used to amplify the Ϫ143/ϩ52 region of CYP2J2 from the purified DNA-protein immune complexes; PCR products were run on 2% agarose gels and visualized after ethidium bromide staining. Controls used in ChIP assays were preimmune homologous IgG and input template DNA. Chromatin samples were diluted 1000-fold before use as template for quantitative PCR analysis. A standard curve was constructed using a serial dilution of CYP2J2 promoter plasmid DNA spanning the Ϫ143/ϩ52 region. The relative fold difference was calculated by the comparative quantitation method and normalized to ␣-tubulin.
Coimmunoprecipitation Assay. HepG2 cells were transfected for 24 h with c-Jun-FLAG (500 ng/6 ϫ 10 5 cells) and either Nrf2, Nrf2mtbZIP, or Nrf2⌬DBD (500 ng) and then lysed in 25 mM HEPES, pH 7.9, containing 10% glycerol, 0.1% Igepal, 5 mM MgCl 2 , 0.5 mM dithiothreitol, 4 g/ml aprotinin, 10 g/ml leupeptin, and 1 g/ml pepstatin. Lysates were incubated overnight with anti-Nrf2 IgG (6 g) at 4°C before pull-down with beads that had been treated with lysis buffer containing 0.5 M KCl. After washing, bound pro- Cloning and Mutagenesis p2J2(Ϫ152/ϩ98; mtϪ105/Ϫ88) 
Results
Activation of CYP2J2 Expression in HepG2 Cells by the Antioxidant BHA. Treatment of HepG2 cells with BHA (20 M) increased CYP2J2 mRNA expression to 182 Ϯ 10, 211 Ϯ 20, and 206 Ϯ 15% of control after 24, 48, and 72 h, respectively (P Ͻ 0.01; Fig. 1A) . The concentration-dependence of CYP2J2 mRNA induction by BHA (10-100 M) was established at 24 h (P Ͻ 0.01 in each case; Fig. 1B) . After BHA treatment, HepG2 cell lysates were also prepared at timed intervals for the estimation of CYP2J2 immunoreactive protein using an antiserum directed against rabbit CYP2J4, which is cross-reactive with human CYP2J2 (Xie et al., 2000) ; ␣-tubulin was used to indicate protein loading (Fig.  1C) . From Fig. 1D , CYP2J2 protein expression was increased at each time point by BHA treatment (100 M). Treatment of HepG2 cells with the related chemical tert-butylhydroquinone (100 M) also increased CYP2J2 mRNA and protein expression similarly to BHA over the time frame of 6 to 72 h in culture (data not shown).
BHA increases Nrf2 expression in cells, and the resultant heterodimers with c-Jun activate a number of phase II genes that are protective against a range of xenobiotics and reactive intermediates (Yu et al., 1997 (Yu et al., , 2000 . c-Jun has been shown previously to activate the human CYP2J2 gene (Marden and Murray, 2005) . Consistent with previous reports (Yu et al., 1997; Yuan et al., 2006) , c-Jun and Nrf2 mRNAs were both increased in HepG2 cells by treatment with BHA (100 M) for 6 and 24 h (P Ͻ 0.05; Fig. 2A ). c-Jun immunoreactive protein was also increased to 8.3 Ϯ 2.3-and 15.5 Ϯ 4.6-fold of control after 6 and 24 h of treatment, respectively (P Ͻ 0.05; Fig. 2B ), and Nrf2 immunoreactive protein was increased to 1.9 Ϯ 0.2-and 2.3 Ϯ 0.1-fold of control after 6 (P Ͻ 0.01) and 24 h (P Ͻ 0.001; Fig. 2A ). ChIP assays confirmed the direct binding of c-Jun and Nrf2 to the CYP2J2 proximal promoter region that was strongly enhanced by treatment of cells with BHA (20 and 100 M; Fig. 2C ). In agreement with these findings, the expression of activated forms of these bZIP factors, phosphoserine 63 -c-Jun and phosphoserine 40 -Nrf2, was increased in lysates from HepG2 cells that had been treated with BHA (100 M) for 0.5 to 6 h (Fig. 2D) .
Molecular Analysis of CYP2J2 Transactivation by c-Jun and Nrf2. CYP2J2 5Ј-flank-luciferase reporter deletion constructs were used to characterize the region of the CYP2J2 upstream sequence that mediated transactivation by c-Jun and Nrf2, which were up-regulated by BHA treatment (Fig. 3A) . The construct p2J2(Ϫ2341/ϩ98) was strongly activated by these factors after individual transfection and to 6.8 Ϯ 0.6-fold of control by the combination of c-Jun/Nrf2 (Fig. 3B) . Deletion constructs were similarly responsive down to the construct p2J2(Ϫ122/ϩ98), but p2J2(Ϫ82/ϩ98) was much less responsive. Thus, the region between Ϫ122 and Ϫ82 seemed to be responsible for c-Jun/Nrf2-dependent transactivation. Consistent with this finding, mutagenesis of the Ϫ105/Ϫ88 region of CYP2J2 attenuated c-Jun/Nrf2 responsiveness [p2J2(Ϫ152/ϩ98; mtϪ105/Ϫ88); Fig. 3B] .
The ؊105/؊88 Region in the CYP2J2 5-Flank Is Involved in the Binding of c-Jun and Nrf2. BHA treatment activated Nrf2 and c-Jun expression in cells and, from ChIP analysis, increased the binding of these factors to the CYP2J2 5Ј-flank. Transient transfection studies strongly implicated the region between Ϫ105/Ϫ88 in the CYP2J2 5Ј-flank in c-Jun/Nrf2-mediated transactivation. This region has been shown previously to harbor an AP-1-like responsive region that binds c-Jun (Marden and Murray, 2005) , but its involvement in Nrf2-mediated augmentation of transactivation by c-Jun has not been considered previously. In the present study, EMSA analysis with the Ϫ118/Ϫ60 probe that spans the putative responsive region (Fig. 4A ) was undertaken to evaluate binding in NP from HepG2 cells, in which c-Jun and Nrf2 had been overexpressed. The resultant DNAprotein complex was competed by unlabeled self-probe but not by the unrelated STAT5 probe from the ␤-casein promoter (Fig. 4B ). An antibody against c-Jun, but not anti- 
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Nrf2, block-shifted the DNA-protein complex; the effect of the anti-c-Jun/anti-Nrf2 combination was similar to that of antic-Jun alone, thus suggesting a pivotal role for c-Jun binding (Fig. 4B) . The nonspecific anti-ubiquitin antibody negative control did not shift the complex. Competitor oligonucleotides corresponding to the CYP2J2 regions at Ϫ105/Ϫ95 and Ϫ99/ Ϫ88, but not the adjacent sequence Ϫ83/Ϫ73, also blocked the binding interaction (Fig. 4C) . Considered together, findings from EMSA, transient transfection, and ChIP assays implicated the Ϫ105/Ϫ88 region of the CYP2J2 upstream region in binding and transactivation by c-Jun and Nrf2.
To corroborate the functional importance of this region of the CYP2J2 5Ј-flank HepG2 cells were transfected with the constructs p2J2(Ϫ152/ϩ98), which contains the Ϫ105/Ϫ88 region, and p2J2(Ϫ49/ϩ98), which does not. BHA treatment (100 M) stimulated the reporter activity of the p2J2(Ϫ152/ ϩ98) construct but not that of p2J2(Ϫ49/ϩ98) (P Ͻ 0.01; Fig.  5A ). In further studies, NP fractions were extracted from BHA-treated HepG2 cells (20 and 100 M) and used in EMSA studies with the Ϫ118/Ϫ60 probe. As shown in Fig.  5B , binding of the 32 P-labeled Ϫ118/Ϫ60 sequence to BHA-NP was enhanced (lanes 2 and 3) compared with control (DMSO-treated)-NP (lane 1). These data are consistent with a major role for the Ϫ105/Ϫ88 region in activation of the CYP2J2 gene by BHA.
Interaction of c-Jun and Nrf2 in the Activation of the CYP2J2 Promoter. ChIP assays established that BHA enhanced the binding of both c-Jun and Nrf2 to the CYP2J2 regulatory region, and supershift EMSAs suggested that cJun may be the critical partner in the binding reaction. To further investigate the nature of the Nrf2/c-Jun interaction a series of mutant expression plasmids was constructed for use in transient transfection assays (Fig. 6A) . As shown in Fig.  6B , the increase in c-Jun-mediated activation of the construct p2J2(Ϫ152/ϩ98) by cotransfected Nrf2 (6.13 Ϯ 0.36-fold of control relative to 3.32 Ϯ 0.31-fold of control by cotransfected c-Jun alone; P Ͻ 0.001) was abolished by the DN-c-Jun plasmid (0.76 Ϯ 0.12-fold of control). In contrast, cotransfection of Nrf2 mutants lacking either the Nrf2 DNA-binding domain (Nrf2⌬DBD), or the transactivation domain (DN-Nrf2), still augmented c-Jun-mediated transactivation of p2J2(Ϫ152/ ϩ98) (p Ͻ 0.001). However, replacement of wild-type Nrf2 with Nrf2mtbZIP, in which Leu537 and Leu544 in the bZIP domain were replaced with alanine residues, significantly attenuated the augmentation by Nrf2 of c-Jun-mediated transactivation (3.63 Ϯ 0.11-fold of control; Fig. 6B ). Thus, the bZIP regions of Nrf2 and c-Jun were implicated in the activation of CYP2J2 reporter constructs, and this finding is consistent with an essential role for c-Jun in transactivation.
Coimmunoprecipitation (CoIP) assays were used to further evaluate the interaction between c-Jun and Nrf2. A FLAG-tagged c-Jun expression plasmid was coexpressed with plasmids encoding either wild-type Nrf2, Nrf2⌬DBD, or Nrf2mtbZIP. After immunoprecipitation with anti-Nrf2 IgG and immunoblotting for the FLAG tag, a weaker signal was observed in the case of the c-Jun-FLAG/Nrf2mtbZIP combination (Fig. 6C, lane 6 ) compared with that with wildtype Nrf2 (lane 4) and Nrf2⌬DBD (lane 5). Immune precipitates in Nrf2mtbZIP-transfected cells also contained less Nrf2, even though the signal from direct immunoblots was similar to that in cells transfected with Nrf2/c-Jun-FLAG. These findings from CoIP experiments support a role for bZIP leucine residues in the c-Jun/Nrf2 interaction, which enhances CYP2J2 transactivation over that elicited by c-Jun alone.
Discussion
The present study has identified BHA as a novel inducer of CYP2J2 expression in human cells. The time-and concentration-dependent increases in CYP2J2 mRNA and protein expression after BHA treatment were closely related to activation of the bZIP transcription factors c-Jun and Nrf2. Furthermore, ChIP analysis indicated that the binding of these factors to the CYP2J2 proximal promoter region was strongly increased by BHA treatment of cells. This region of the CYP2J2 gene has been shown previously to harbor elements responsive to c-Jun and to mediate CYP2J2 downregulation in hypoxia (Marden et al., 2003; Marden and Murray, 2005) , but the present findings now establish that heterodimers formed between Nrf2 and c-Jun up-regulate CYP2J2. Moreover, agents that activate the expression of bZIP transcription factors from the AP-1 family regulate a large number of genes, and response elements for AP-1 are common throughout the genome. However, a number of AP-1-responsive genes contain atypical AP-1 response elements such that heterodimerization between alternate bZIP factors may influence the fine-tuning of transcriptional responses (McBride and Nemer, 1998; Venugopal and Jaiswal, 1998; Vinson et al., 2006) . In the case of the murine interleukin-4 gene, for example, the apparent AP-1-responsive region is unrelated to the AP-1 consensus sequence (Rooney et al., 1995) . Atypical AP-1-responsive gene elements that may accommodate a number of alternate bZIP factors have also been found in the osteocalcin and secreted protein acidic and rich in cysteine genes, among others (Vial et al., 2000; Akhouayri and St-Arnaud, 2007) . In the present study, transient transfection and EMSA analysis were used to identify the Ϫ105/Ϫ88-base pair region of the CYP2J2 gene 5Ј-flank as an atypical bZIP binding sequence that was responsive to c-Jun/Nrf2 dimers.
c-Jun seemed to have the critical role in transactivation of CYP2J2 by c-Jun/Nrf2 dimers. Thus, a dominant-negative mutant expression plasmid that lacked the transactivation domain abolished CYP2J2 activation. In contrast, Nrf2 mutants lacking either the transactivation or DNA-binding domain behaved like wild-type Nrf2; thus, augmentation of c-Jun-dependent transactivation remained. Instead, an Nrf2 mutant in which alanine residues replaced critical fifth and sixth leucine residues within the bZIP domain at Leu537 and Leu544, which are essential for dimerization and nuclear retention (Li et al., 2008) , significantly decreased CYP2J2 transactivation. EMSA findings also supported a major role for c-Jun. Thus, anti-c-Jun elicited a block shift, consistent with disruption of the interaction between c-Jun and the labeled oligonucleotide probe, whereas an anti-Nrf2 antibody weakly supershifted the complex, consistent with a decrease in electrophoretic mobility. Taken together, these experiments strongly suggest that c-Jun and Nrf2-mediated activation of CYP2J2 at the Ϫ105/Ϫ88 element region is highly dependent on c-Jun. The synthetic phenolic antioxidant BHA is an effective in vivo inducer of phase II genes in mammals and exerts protective effects against toxic xenobiotics (Chung et al., 1986; Williams and Iatropoulos, 1996) . The underlying mechanism involves activation of the bZIP transcription factor Nrf2 (Yu et al., 1997; Venugopal and Jaiswal, 1998; Yuan et al., 2006) . Thus, pro-oxidant and antioxidant agents modulate the cytoplasmic association of Nrf2 with the cysteine-rich scaffold protein kelch-like ECH-associated protein 1 that is attached to the cytoskeleton (Dinkova-Kostova et al., 2002; Wakabayashi et al., 2004) . Modification of the cysteine sulfhydryls in kelch-like ECH-associated protein 1 enables Nrf2 dissociation and facilitates its entry to the nucleus, in which it undergoes phosphorylation and may dimerize with other bZIP factors and bind to antioxidant-response elements in the promoters of cytoprotective genes (Venugopal and Jaiswal, 1998; Huang et al., 2000) . The present findings indicate that CYP2J2 is also an antioxidant-inducible Nrf2-regulated gene and that dimerization with c-Jun is important in transactivation. Other members of the antioxidant-inducible gene battery, including the ␥-glutamylcysteine synthaseheavy subunit NADPH-quinone oxidoreductase-1 and glutathione transferase Ya genes, are also transactivated by Nrf2 Fig. 5 . A, activation of the reporter construct p2J2(Ϫ152/ϩ98) but not p2J2(-49/ϩ98) in transfected cells by BHA treatment (100 M). B, EMSA analysis using the Ϫ118/Ϫ60 oligonucleotide probe in nuclear protein fractions from HepG2 cells that had been treated with BHA (20 or 100 M), relative to DMSO-treated control (CTL; shift indicated by arrow). Reporter data are means Ϯ S.E.M. of three independent experiments performed at least in triplicate. Different from corresponding control (reporter activity in the absence of BHA treatment): ‫,ءء‬ P Ͻ 0.01. Representative EMSAs are shown from experiments performed in duplicate. in processes that are highly dependent on cellular c-Jun expression (Jeyapaul and Jaiswal, 2000; Jaiswal, 2004) . BHA is the first agent identified to date that activates CYP2J2 gene expression in human cells. Alternate agents, such as sulforaphane, that also activate bZIP factor expression have been found to exert protective effects in cells and in in vivo models of experimental injury (Yoon et al., 2008; Higgins et al., 2009) . In view of the proliferative and mitogenic actions of EETs, it is now of interest to evaluate the specific role of CYP2J2 in the overall cytoprotective actions of such agents.
